High throughput assay for the determination of piperaquine in plasma

被引:31
作者
Lindegårdh, N
White, NJ
Day, NPJ
机构
[1] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand
[2] Univ Oxford, Ctr Trop Med, Nuffield Dept Clin Med, Oxford OX1 2JD, England
基金
英国惠康基金;
关键词
antimalarial; high throughput; liquid chromatography; piperaquine; solid phase extraction; 96-well;
D O I
10.1016/j.jpba.2005.03.031
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A high throughput assay for the determination of the antimalarial piperaquine in plasma has been developed and validated. The assay utilises 96-wellplate formats throughout the whole procedure, and easily enables a throughput of 192 samples a day using a single LC system. Buffer (pH 2.0; 0.05 M) containing internal standard was added to 0.25 mL plasma in a 96-wellplate (2 mL wells). The samples were extracted on a MPC solid phase extraction deep well 96-wellplate (3 M Empore). Piperaquine and internal standard were analysed by liquid chromatography with UV detection on a Chromolith Performance (100 mm x 4.6 mm) column with a mobile phase containing acetonitrile-phosphate buffer (pH 2:5; 0.1 M) (8:92, v/v) at a flow rate of 3.0 mL/min. The within-day precisions for piperaquine were 3.3 and 2.3% at 40 and 1250 ng/mL, respectively. The between-day precisions for piperaquine were 5.8 and 1.3% at 40 and 1250 ng/mL, respectively. The total assay precisions using 29 replicates over 5 days were 6.7, 4.5 and 2.7% at 40, 200 and 1250 ng/mL, respectively. The lower limit of quantification (LLOQ) and the limit of detection (LOD) were 10 and 5 ng/mL, respectively using 0.25 mL plasma. Using I mL of plasma, it was possible to decrease LLOQ and LOD to 2.5 and 1.25 ng/mL, respectively. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:601 / 605
页数:5
相关论文
共 20 条
[1]   Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods [J].
Almeida, AM ;
Castel-Branco, MM ;
Falcao, AC .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 774 (02) :215-222
[2]  
ARONSSON T, 1984, SCAND J CLIN LAB INV, V44, P51
[3]  
CHEN L, 1991, CHINESE MED J-PEKING, V104, P161
[4]  
CHEN L, 1982, CHINESE MED J-PEKING, V95, P281
[5]  
*DEP HHS FOOD DRUG, 2001, GUID IND BIOAN METH
[6]   CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam [J].
Giao, PT ;
de Vries, PJ ;
Hung, LQ ;
Binh, TQ ;
Nam, NV ;
Kager, PA .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2004, 9 (02) :209-216
[7]   Validation of bioanalytical chromatographic methods [J].
Hartmann, C ;
Smeyers-Verbeke, J ;
Massart, DL ;
McDowall, RD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (02) :193-218
[8]   Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam:: randomised clinical trial [J].
Hien, TT ;
Dolecek, C ;
Mai, PP ;
Dung, NT ;
Truong, NT ;
Thai, LH ;
An, DTH ;
Thanh, TT ;
Stepniewska, K ;
White, NJ ;
Farrar, J .
LANCET, 2004, 363 (9402) :18-22
[9]  
Hung TY, 2004, BRIT J CLIN PHARMACO, V57, P253, DOI [10.1046/j.1365-2125.2003.02004.x, 10.1111/j.1365-2125.2003.02004.x]
[10]   Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection [J].
Hung, TY ;
Davis, TME ;
Ilett, KF .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 791 (1-2) :93-101